| Identification | Back Directory | [Name]
Tat-NR2Baa | [CAS]
847829-41-8 | [Synonyms]
Tat-NR2Baa
L-Alanine, L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl-L-arginyl-L-lysyl-L-leucyl-L-seryl-L-seryl-L-isoleucyl-L-α-glutamyl-L-alanyl-L-α-aspartyl- | [Molecular Formula]
C103H184N42O29 | [MOL File]
847829-41-8.mol | [Molecular Weight]
2474.87 |
| Chemical Properties | Back Directory | [density ]
1.52±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [form ]
Solid | [color ]
White to off-white | [Sequence]
Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Leu-Ser-Ser-Ile-Glu-Ala-Asp-Ala |
| Hazard Information | Back Directory | [Uses]
Tat-NR2BAA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95[1][2]. | [IC 50]
NMDA Receptor | [storage]
Store at -20°C | [References]
[1] Michelle Aarts, et al. Treatment of Ischemic Brain Damage by Perturbing NMDA Receptor- PSD-95 Protein Interactions. Science DOI:10.1126/science.1072873 |
|
|